Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) Short Interest Down 14.0% in June

Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) was the target of a significant decrease in short interest during the month of June. As of June 15th, there was short interest totalling 47,353,700 shares, a decrease of 14.0% from the May 31st total of 55,038,700 shares. Based on an average daily trading volume, of 2,945,900 shares, the short-interest ratio is currently 16.1 days.

Northwest Biotherapeutics Price Performance

Shares of OTCMKTS NWBO opened at $0.43 on Friday. The firm has a fifty day moving average price of $0.46 and a 200-day moving average price of $0.55. The stock has a market cap of $524.63 million, a PE ratio of -6.10 and a beta of -0.63. Northwest Biotherapeutics has a 1 year low of $0.40 and a 1 year high of $1.09.

Northwest Biotherapeutics (OTCMKTS:NWBO) last announced its quarterly earnings data on Friday, May 10th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter. The firm had revenue of $0.28 million for the quarter.

Northwest Biotherapeutics Company Profile

Northwest Biotherapeutics, Inc, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer.